| Avonex (recombinant IFN-β-1a) / Biogen |
NCT00037115: Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. |
|
|
| Withdrawn | 4 | 0 | US | interferon beta 1a, methotrexate, methylprednisolone | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute, Consultants in Neurology | Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis, Neuritis | 12/02 | 12/02 | | |
| Completed | 4 | 408 | US | Interferon beta-1a (Avonex), Avonex | Biogen | Multiple Sclerosis | 06/03 | 07/03 | | |
NCT00037102: Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis |
|
|
| Completed | 4 | 16 | NA | interferon beta 1a, methotrexate | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute, Consultants in Neurology, Biogen | Multiple Sclerosis | 12/03 | 12/03 | | |
NCT00913666: Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers |
|
|
| Completed | 4 | 121 | US | Interferon beta-1a (Avonex), Avonex | Biogen | Multiple Sclerosis | | 11/04 | | |
NCT00206648: An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS |
|
|
| Completed | 4 | 271 | US, Canada | Betaferon/Betaseron | Bayer | Multiple Sclerosis, Relapsing-Remitting | | 10/05 | | |
| Completed | 4 | 155 | US, Canada | interferon beta 1a 30 ug IM once weekly | Beth Israel Deaconess Medical Center, Biogen | Multiple Sclerosis, Optic Neuritis, Transverse Myelitis, Acute Brainstem/Cerebellar Syndrome | 03/09 | 03/09 | | |
|
NCT00246324: Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis |
|
|
| Completed | 4 | 16 | US | Interferon beta 1a, oral doxycycline, Avonex | Louisiana State University Health Sciences Center Shreveport, Biogen | Multiple Sclerosis | 08/09 | 10/09 | | |
PRTOECT, NCT00771043: A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a |
|
|
| Withdrawn | 4 | 50 | NA | TYSABRI and AVONEX | Biogen | Relapsing-remitting Multiple Sclerosis | 08/09 | 06/10 | | |
EPOC, NCT01216072: A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis |
|
|
| Completed | 4 | 1053 | US, Canada | Fingolimod, GILENYA™, Standard MS DMTs, Avonex®,, Copaxone®,, Rebif®,, Betaseron®,, Extavia® | Novartis Pharmaceuticals | Relapsing Forms of Multiple Sclerosis | 08/12 | 08/12 | | |
|
|
|
|
NCT00101959: Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects |
|
|
| Withdrawn | 4 | 0 | US | Rebif | EMD Serono | Relapsing-Remitting Multiple Sclerosis | | | | |
| Completed | 4 | 61 | Europe | Fingolimod, GILENYA™, Standard MS DMT, Avonex®,, Copaxone®,, Rebif®,, Betaferon®,, Extavia® | Novartis Pharmaceuticals | Relapsing Remitting Multiple Sclerosis | 06/14 | 06/14 | | |
2005-001281-13: Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET Study) |
|
|
| Completed | 4 | 220 | Europe | Avonex, Interferonum beta-1a, AVONEX, AVONEX | DSC Services, s.r.o. | Clinically isolated syndrome suspected from demyelinating event (no better explanation for present symptoms) | | 01/14 | | |
